Is there anyone who cannot live longer than a year on Palbociclib?

In clinical trials, palbociclib (Palbociclib) combined with letrozole can significantly improve progression-free survival (PFS) in patients with metastatic breast cancer who have not previously received endocrine therapy. The results showed that PFS increased from 4.5 months to 9.5 months, and the overall response rate (ORR) was 24.6%. Each patient's situation is different, including the type of breast cancer, the patient's overall health and other factors, and there are no trials looking at whether patients taking palbociclib survive past one year.

For breast cancer patients treated with palbociclib, doctors will develop a personalized treatment plan based on the patient's specific situation. Palbociclib is often combined with other medications to enhance its effectiveness. During treatment, the patient's lifestyle, eating habits and psychological state will also affect the treatment effect. Breast cancer survival rates have improved significantly in recent years, thanks to earlier diagnosis and more effective treatments. Many patients achieve long-term survival or even complete recovery with a comprehensive treatment regimen.

The original drug of palbociclib has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be more than more than 4,000 yuan. The price of palbociclib's original drug, 125mg*21 capsules, per box sold overseas may be more than RMB 10,000 (the price may fluctuate due to exchange rates). There are also generic palbociclib drugs produced in other countries. The price of 125mg*21 tablets produced by a Bangladeshi pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to the exchange rate). The price is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.